Amin Sharifan, PharmD

Dobrescu, A.I.; Pinte, L.; Sharifan, A.; Gadinger, A.; Moser, I.; Cooper, C.; Gartlehner, G. (2026). Effectiveness, Comparative Effectiveness, and Harms of COVID-19 Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians. Annals of Internal Medicine, Online ahead of print: 10.7326/ANNALS-25-05044.

GBD 2021 AEMT Collaborators; Sharifan, A. (2026). Global burden of adverse effects of medical treatment from 1990 to 2021: a Global Burden of Disease Study 2021. Korean J Intern Med, 41(2): 350-366

GBD 2023 Breast Cancer Collaborators; Sharifan, A. (2026). Global, regional, and national burden of breast cancer among females, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet Oncology, Volume 27, Issue 3: 302-326

GBD 2023 IHD & Dietary Risk Factors Collaborators; Sharifan, A. (2026). Global, regional and national burden of ischemic heart disease attributable to suboptimal diet, 1990–2023: a Global Burden of Disease study. Nature Medicine, 32: 1454-1478

GBD 2023 Iran Collaborators; Sharifan, A.; et. al. (2026). Burden of 292 causes of death and life expectancy decomposition in Iran, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet Global Health, 14(5): e734-e748

GBD 2023 Maternal Mortality Collaborators; Sharifan, A. (2026). Global, regional, and national levels and trends in maternal mortality, progress towards the Sustainable Development Goals, and mortality from COVID-19 infection in pregnant women, 1990–2023: a systematic analysis for the Global Burden of Disease Study 23. Lancet Obstet Gynaecol Womens Health, 2 (5): e375-e424

GBD 2023 Meningitis & Antimicrobial Resistance Collaborators; Sharifan, A. (2026). Global, regional, and national burden of meningitis, its risk factors, and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet Neurology, 25(5): P451-468

Kang, J.; et. al.; Sharifan, A. (2026). Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study. Nature Medicine, 32: 527-544

Moser, T.K.; Dobrescu, A.I.; Sommer, I.; Goeschl, S.; Sharifan, A.; Ledinger, D.; Klerings, I.; Gartlehner, G. (2026). Efficacy, Comparative Effectiveness, and Harm of Respiratory Syncytial Virus Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians. Annals of Internal Medicine, Online ahead of print: 10.7326/ANNALS-25-05536.

Oh, J.; et. al.; Sharifan, A. (2026). Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990–2023: a Global Burden of Disease study. Nature Medicine, 32: 197-223

Sharifan, A. (2026). Misrepresentation of nonsignificant results: reporting pitfalls in urology randomised trials. BJU International, https://doi.org/10.1111/bju.70139: https://doi.org/10.1111/bju.70139

Sharifan, A.; Dobrescu, A.I.; Klerings, I.; Gartlehner, G. (2026). Update Alert 4: Nonpharmacologic and Pharmacologic Treatments of Adult Patients With Major Depressive Disorder: A Systematic Review and Network Meta-analysis for a Clinical Guideline by the American College of Physicians. Annals of Internal Medicine, Online ahead of print: 10.7326/ANNALS-26-00504.

Sharifan, A.; Gadinger, A.; Cooper, C.; Braun, A. (2026). Vitrectomy After Cataract Surgery as a Patient Safety Indicator: A Rapid Review to Support Benchmarking Within the Austrian Inpatient Quality Indicators Framework. Journal of Patient Safety, 10.1097: 1-11

Sharifan, A.; Harrod, C.; Dobrescu, A.; Gartlehner, G. (2026). Reverse fragility index shows high fragility in Cochrane meta-analyses with P values between 0.05 and 0.20: a meta-epidemiological study. Journal of Clinical Epidemiology, 195: https://doi.org/10.1016/j.jclinepi.2026.112285

Sommer, I. Dobrescu, A. Gadinger, A. Sharifan, A. Pinte, L. Fangmeyer, M. Klerings, I. Gartlehner, G. (2026). Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Review for the American College of Physicians (Version 3). Annals of Internal Medicine, Online ahead of print: 10.7326/ANNALS-25-03691.

Ryan-Vig, S.; Sharifan, A. (2026). For people undergoing first-line treatment for advanced pancreatic cancer, how do gemcitabine-containing dual chemotherapy regimens compare with gemcitabine alone? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4689: https://doi.org/10.1002/cca.4689

Ryan-Vig, S.; Sharifan, A. (2026). What are the benefits and harms of different interventions for people interested in quitting nicotine-containing vapes? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4746: https://doi.org/10.1002/cca.4746

Sharifan, A. (2026). For people undergoing first-line treatment for advanced pancreatic cancer, how do different chemotherapy combinations compare with gemcitabine plus nab-paclitaxel? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4691: https://doi.org/10.1002/cca.4691

Sharifan, A. (2026). In children with nocturnal enuresis, how does desmopressin therapy alone compare with desmopressin combination therapy (adding alarm therapy or other medications, such as anticholinergics or tricyclics)? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4711: https://doi.org/10.1002/cca.4711

Sharifan, A. (2026). For adults with obesity, what are the benefits and harms of semaglutide injections compared with liraglutide injections? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4732: https://doi.org/10.1002/cca.4732